Aymeric Sève - Concepedia

Author

Aymeric Sève

Centre hospitalier universitaire d'Orléans

Also Known As

A. Seve, A. Sève, A.L. Denis Le Seve, Amen Sergew, Aymeric Seve, Aymeric SÈVE, Aymeric Sève, C Gubavu, K Risso, Seve, Aymeric

Publications

Citations

H-Index

Concepts

All Affiliations

Centre hospitalier universitaire d'Orléans Inserm Université Paris Cité Sorbonne Université Centre National de la Recherche Scientifique

About

Aymeric Sève is an author at Centre hospitalier universitaire d'Orléans specializing in immunology, medicine, and covid-19.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	5.6K
2	Immunology	12	12	5.6K
3	Epidemiology	3	3	401
4	Allergy	2	2	74
5	Public Health	1	1	21

Aymeric Sève

Publications

5.8K

Citations

H-Index

Page 1

	Year	Citations
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization Delphine Planas, David Veyer, Artem Baidaliuk, Nature Reduced SensitivityVaccine TargetImmunologyAntibody EngineeringImmunotherapy	2021	2.2K
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization Delphine Planas, Nell Saunders, Piet Maes, Nature Vaccine TargetImmunologyAntibody ScreeningAntibody EngineeringImmunotherapy	2021	1.6K
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies Delphine Planas, Timothée Bruel, Ludivine Grzelak, Nature Medicine Viral DiagnosticsVaccine TargetImmunologyVirologyInfectious Sars-cov-2 B.1.1.7	2021	766
Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies Timothée Bruel, Jérôme Hadjadj, Piet Maes, Nature Medicine Humoral ResponseImmunologySerologic TestingAntibody ScreeningMonoclonal Antibodies	2022	305
Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals Delphine Planas, David Veyer, Artem Baidaliuk, Viral DiagnosticsImmunologyImmunodominanceCovid-19Viral Evolution	2021	282
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization Delphine Planas, Nell Saunders, Piet Maes, Nature Vaccine TargetImmunologyAntibody ScreeningAntibody EngineeringImmunotherapy	2021	213
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies Delphine Planas, Timothée Bruel, Ludivine Grzelak, Viral DiagnosticsImmunodeficienciesNasal SwabsImmunologyImmunodominance	2021	107
Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization Delphine Planas, Nell Saunders, Piet Maes, Viral DiagnosticsImmunodeficienciesImmunologyImmunodominanceCovid-19	2021	98
Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial Jean‐Jacques Parienti, Thiérry Prazuck, Laure Peyro‐Saint‐Paul, EClinicalMedicine	2021	64
Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies Timothée Bruel, Karl Stéfic, Yann Nguyen, Cell Reports Medicine Identical Neutralization ProfilesAllergyHumoral ResponseImmunologyTherapeutic Mabs	2022	57

Page 1